



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Laura Moro
laura.moro@uniupo.it
Giulia Pinton
giulia.pinton@uniupo.it

SPECIALTY SECTION

This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Oncology

RECEIVED 27 October 2022

ACCEPTED 31 October 2022

PUBLISHED 23 November 2022

CITATION

Pinton G, Wang Z, Balzano C,
Missaglia S, Tavian D, Boldorini R,
Fennell DA, Griffin M and Moro L
(2022) Corrigendum: *CDKN2A*
determines mesothelioma cell fate to
EZH2 inhibition.
Front. Oncol. 12:1081632.
doi: 10.3389/fonc.2022.1081632

COPYRIGHT

© 2022 Pinton, Wang, Balzano,
Missaglia, Tavian, Boldorini, Fennell,
Griffin and Moro. This is an open-access
article distributed under the terms of
the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution
or reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: *CDKN2A* determines mesothelioma cell fate to EZH2 inhibition

Giulia Pinton^{1*}, Zhuo Wang², Cecilia Balzano¹, Sara Missaglia³,
Daniela Tavian³, Renzo Boldorini⁴, Dean A. Fennell⁵,
Martin Griffin² and Laura Moro^{1*}

¹Department of Pharmaceutical Sciences, University of Piemonte Orientale (UPO), Novara, Italy, ²School of Life and Health Sciences, Aston University, Birmingham, United Kingdom, ³Laboratory of Cellular Biochemistry and Molecular Biology, Centro di Ricerca in Biochimica E Nutrizione dello Sport (CRIBENS), Catholic University of the Sacred Heart, Milan, Italy, ⁴Department of Health Science, University of Piemonte Orientale (UPO), Novara, Italy, ⁵Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom

KEYWORDS

malignant pleural mesothelioma, EZH2 inhibitor, *CDKN2A/p16^{ink4a}*, TG2, multicellular spheroids

A corrigendum on

CDKN2A determines mesothelioma cell fate to EZH2 inhibition

by Pinton G, Wang Z, Balzano C, Missaglia S, Tavian D, Boldorini R, Fennell DA, Griffin M and Moro L (2021). *Front. Oncol.* 11:678447. doi: 10.3389/fonc.2021.678447

In the original article, there was an error in the Funding statement as published. The correct funding statement is “The authors acknowledge the financial support of project HERMES (HEReditary Risk in MESothelioma) and Università del Piemonte Orientale (Bando ricerca locale 2019)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.